# Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer

> **NCT01650376** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Swedish Medical Center** · enrollment: 52 (estimated)

## Conditions studied

- Stage III Ovarian Cancer
- Stage IV Ovarian Cancer
- Uterine Cancer

## Interventions

- **DRUG:** Olaparib
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT01650376
- **Lead sponsor:** Swedish Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-08
- **Primary completion:** 2018-12
- **Final completion:** 2019-12
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2018-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01650376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01650376, "Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01650376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*